Filings
| Filing | Date | Type | Filed with |
|---|
| 6-K · Report of a foreign issuer | Nov 19, 2026 | Current report | SEC |
|---|
| Encouraging Disease-Free Survival in Phase II Sarcoma Trial | Nov 18, 2026 | Operations update | ASX |
|---|
| Immutep Investor Update | Nov 17, 2026 | Other filings | ASX |
|---|
| Immutep Expands US Patents for Efti Combination Therapies | Nov 10, 2026 | Other filings | ASX |
|---|
| EFTISARC-NEO Survival Data reported in CTOS 2026 Abstract | Nov 10, 2026 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Nov 10, 2026 | Current report | SEC |
|---|
| IMP761 Late-Breaking Abstract at ACR shows T-Cell Inhibition | Nov 8, 2026 | Operations update | ASX |
|---|
| Upcoming Poster Presentations at CTOS and ESMO IO 2026 | Nov 4, 2026 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Oct 30, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Oct 29, 2026 | Current report | SEC |
|---|
| Immutep Quarterly Activities Report and Appendix 4C | Oct 28, 2026 | Quarterly report | ASX |
|---|
| Immutep Receives A$2.16 million French R&D Tax Incentive | Oct 27, 2026 | Financing | ASX |
|---|
| Notice of Annual General Meeting/Proxy Form | Oct 26, 2026 | Meeting notice | ASX |
|---|
| Appendix 4G and Corporate Governance Statement | Oct 26, 2026 | Other filings | ASX |
|---|
| Annual Report to shareholders | Oct 26, 2026 | Annual report | ASX |
|---|
| Annual Report filed on Form 20-F | Oct 25, 2026 | Annual report | ASX |
|---|
| 20-F · Annual report | Oct 23, 2026 | Annual report | SEC |
|---|
| Quality of Life Data from EFTISARC-NEO presented at ESMO | Oct 23, 2026 | Operations update | ASX |
|---|
| Late-Breaking Abstract on IMP761 to be presented at ACR 2026 | Oct 18, 2026 | Other filings | ASX |
|---|
| 2026 Annual General Meeting and Key Dates | Oct 14, 2026 | Meeting notice | ASX |
|---|
| 6-K · Report of a foreign issuer | Oct 13, 2026 | Current report | SEC |
|---|
| Immutep & Monash Secure Further ARC Funding for LAG-3 | Oct 13, 2026 | Other filings | ASX |
|---|
| Immutep Regains Compliance with Nasdaq | Oct 12, 2026 | Compliance certificate | ASX |
|---|
| Audit and Risk Committee Update | Oct 9, 2026 | Other filings | ASX |
|---|
| Final Director's Interest Notice - P Meyers | Oct 4, 2026 | List of directors | ASX |
|---|
| Notification of cessation of securities - IMM | Oct 4, 2026 | Financing | ASX |
|---|
| Resignation of Non-Executive Director | Oct 4, 2026 | Management or board change | ASX |
|---|
| Change of Director's Interest Notice - P Meyers | Sep 30, 2026 | Ownership change notice | ASX |
|---|
| Application for quotation of securities - IMM | Sep 30, 2026 | Financing | ASX |
|---|
| Immutep receives Australian R&D Tax Incentive | Sep 29, 2026 | Financing | ASX |
|---|
| 6-K · Report of a foreign issuer | Sep 22, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Sep 11, 2026 | Current report | SEC |
|---|
| Immutep Outlines Focused Development Strategy for Efti | Sep 10, 2026 | Operations update | ASX |
|---|
| S&P DJI Announces September 2026 Quarterly Rebalance | Sep 4, 2026 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Sep 1, 2026 | Current report | SEC |
|---|
| Appendix 4E & 2026 Full Year Statutory Accounts | Aug 30, 2026 | Annual report | ASX |
|---|
| Immutep Corporate Presentation | Aug 19, 2026 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Jul 31, 2026 | Current report | SEC |
|---|
| Immutep Quarterly Activities Report and Appendix 4C | Jul 29, 2026 | Quarterly report | ASX |
|---|
| 6-K · Report of a foreign issuer | Jul 13, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jun 4, 2026 | Current report | SEC |
|---|
| UPLOAD · Letter from the SEC | May 11, 2026 | Other filings | SEC |
|---|
| 6-K · Report of a foreign issuer | May 1, 2026 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 30, 2026 | Current report | SEC |
|---|
| CORRESP · Letter to the SEC | Apr 24, 2026 | Other filings | SEC |
|---|
| 3 · Initial statement of ownership | Apr 16, 2026 | Insider trade | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 15, 2026 | Current report | SEC |
|---|
| Immutep receives FDA ODD for Efti in Soft Tissue Sarcoma | Apr 14, 2026 | Operations update | ASX |
|---|
| 3 · Initial statement of ownership | Apr 13, 2026 | Insider trade | SEC |
|---|
| 3 · Initial statement of ownership | Apr 13, 2026 | Insider trade | SEC |
|---|
| 3 · Initial statement of ownership | Apr 7, 2026 | Insider trade | SEC |
|---|
| UPLOAD · Letter from the SEC | Apr 7, 2026 | Other filings | SEC |
|---|
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
|---|
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
|---|
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
|---|
| 3 · Initial statement of ownership | Apr 1, 2026 | Insider trade | SEC |
|---|
| 6-K · Report of a foreign issuer | Mar 19, 2026 | Current report | SEC |
|---|
| Update on Phase I Study of IMP761 for Autoimmune Diseases | Mar 18, 2026 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Mar 16, 2026 | Current report | SEC |
|---|
| Reinstatement to Quotation | Mar 12, 2026 | Trading halt or suspension | ASX |
|---|
| TACTI-004 to be discontinued following futility analysis | Mar 12, 2026 | Operations update | ASX |
|---|
| Suspension from Quotation | Mar 10, 2026 | Trading halt or suspension | ASX |
|---|
| Trading Halt | Mar 6, 2026 | Trading halt or suspension | ASX |
|---|
| 6-K · Report of a foreign issuer | Feb 25, 2026 | Current report | SEC |
|---|
| Half Yearly Report and Accounts | Feb 24, 2026 | Interim report | ASX |
|---|
| 6-K · Report of a foreign issuer | Feb 9, 2026 | Current report | SEC |
|---|
| Immutep Achieves 50% Enrolment in Global TACTI-004-1L NSCLC | Feb 5, 2026 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Jan 29, 2026 | Current report | SEC |
|---|
| Immutep Quarterly Activities Report and Appendix 4C | Jan 29, 2026 | Quarterly report | ASX |
|---|
| 6-K · Report of a foreign issuer | Dec 22, 2025 | Current report | SEC |
|---|
| Positive Update on IMP761 Phase 1 | Dec 21, 2025 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Dec 16, 2025 | Current report | SEC |
|---|
| TACTI-004 phase III trial enrolment continues at robust pace | Dec 15, 2025 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Dec 9, 2025 | Current report | SEC |
|---|
| Immutep enters into Strategic Collaboration with Dr. Reddy's | Dec 8, 2025 | Acquisition or disposal | ASX |
|---|
| 6-K · Report of a foreign issuer | Dec 2, 2025 | Current report | SEC |
|---|
| New data presentation from AIPAC-003 Phase II for SABCS | Dec 1, 2025 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Nov 13, 2025 | Current report | SEC |
|---|
| EFTISARC-NEO Phase II results presented at CTOS 2025 | Nov 12, 2025 | Results | ASX |
|---|
| 6-K · Report of a foreign issuer | Nov 3, 2025 | Current report | SEC |
|---|
| Immutep Receives A$4.6 million French R&D Tax Incentive | Nov 2, 2025 | Financing | ASX |
|---|
| 6-K · Report of a foreign issuer | Oct 30, 2025 | Current report | SEC |
|---|
| 20-F · Annual report | Oct 24, 2025 | Annual report | SEC |
|---|
| 6-K · Report of a foreign issuer | Oct 21, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Oct 20, 2025 | Current report | SEC |
|---|
| Primary Endpoint Met in STS Trial - presented at ESMO 2025 | Oct 19, 2025 | Results | ASX |
|---|
| Improved ORR in First Line NSCLC - presented at ESMO 2025 | Oct 19, 2025 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Oct 14, 2025 | Current report | SEC |
|---|
| Successful Completion of FDA Project Optimus Requirements | Oct 12, 2025 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Oct 9, 2025 | Current report | SEC |
|---|
| TACTI-004 (KEYNOTE-F91) Phase 3 update in First Line NSCLC | Oct 8, 2025 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Sep 22, 2025 | Current report | SEC |
|---|
| New investigator-initiated Phase II trial for Efti | Sep 21, 2025 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Sep 2, 2025 | Current report | SEC |
|---|
| Appendix 4E & 2025 Full Year Statutory Accounts | Aug 28, 2025 | Annual report | ASX |
|---|
| 6-K · Report of a foreign issuer | Aug 6, 2025 | Current report | SEC |
|---|
| FDA feedback received for head & neck cancer in CPS below 1 | Aug 4, 2025 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Jul 30, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jun 23, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | May 27, 2025 | Current report | SEC |
|---|
| Primary Endpoint Met in Phase II Soft Tissue Sarcoma Trial | May 25, 2025 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | May 15, 2025 | Current report | SEC |
|---|
| High Response Rates achieved in Lung Cancer in INSIGHT-003 | May 14, 2025 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | May 5, 2025 | Current report | SEC |
|---|
| Excellent Overall Survival in Head & Neck Cancer Patients | May 4, 2025 | Results | ASX |
|---|
| 6-K · Report of a foreign issuer | Apr 29, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Mar 25, 2025 | Current report | SEC |
|---|
| First patient dosed in phase 3 TACTI-004 lung cancer trial | Mar 24, 2025 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Feb 27, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Feb 3, 2025 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Dec 17, 2024 | Current report | SEC |
|---|
| Immutep announces initial safety data from IMP761 phase 1 | Dec 16, 2024 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Dec 12, 2024 | Current report | SEC |
|---|
| Immutep Reports Promising New Data in Head and Neck Cancer | Dec 11, 2024 | Results | ASX |
|---|
| 6-K · Report of a foreign issuer | Dec 10, 2024 | Current report | SEC |
|---|
| Initiation of TACTI-004 phase 3 trial in 1st line NSCLC | Dec 9, 2024 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Nov 15, 2024 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Nov 14, 2024 | Current report | SEC |
|---|
| Excellent Survival Data from INSIGHT-003 Trial in NSCLC | Nov 13, 2024 | Results | ASX |
|---|
| Positive Data from Phase II Trial in Soft Tissue Sarcoma | Nov 13, 2024 | Other filings | ASX |
|---|
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Oct 29, 2024 | Current report | SEC |
|---|
| 20-F · Annual report | Oct 22, 2024 | Annual report | SEC |
|---|
| 6-K · Report of a foreign issuer | Oct 3, 2024 | Current report | SEC |
|---|
| Enrolment for Ph II AIPAC-003 Breast Cancer Trial Completed | Oct 3, 2024 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Sep 24, 2024 | Current report | SEC |
|---|
| Immutep receives A$3.6 million French R&D Tax Incentive | Sep 23, 2024 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Sep 16, 2024 | Current report | SEC |
|---|
| New Positive Efficacy Data for Efti in Head and Neck Cancer | Sep 15, 2024 | Results | ASX |
|---|
| 6-K · Report of a foreign issuer | Sep 9, 2024 | Current report | SEC |
|---|
| S&P DJI Announces September 2024 Quarterly Rebalance | Sep 6, 2024 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Sep 3, 2024 | Current report | SEC |
|---|
| Appendix 4E & 2024 Full Year Statutory Accounts | Aug 30, 2024 | Annual report | ASX |
|---|
| 6-K · Report of a foreign issuer | Aug 20, 2024 | Current report | SEC |
|---|
| TACTI-003 data selected for oral presentation at ESMO 2024 | Aug 20, 2024 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Aug 14, 2024 | Current report | SEC |
|---|
| First Participant Dosed in Phase I Study of IMP761 | Aug 13, 2024 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Jul 31, 2024 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jul 23, 2024 | Current report | SEC |
|---|
| Successful Meeting with FDA on Phase III Design in NSCLC | Jul 21, 2024 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Jul 17, 2024 | Current report | SEC |
|---|
| Regulatory Clearance received for Phase 1 trial of IMP761 | Jul 16, 2024 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Jul 12, 2024 | Current report | SEC |
|---|
| Webcast to discuss data presented at ESMO Plenary Session | Jul 11, 2024 | Operations update | ASX |
|---|
| Positive results in TACTI-003 for 1L HNSCC cohort B patients | Jul 11, 2024 | Results | ASX |
|---|
| 6-K · Report of a foreign issuer | Jul 3, 2024 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jun 28, 2024 | Current report | SEC |
|---|
| Webcast slides for new Efti clinical data in 1st line HNSCC | Jun 26, 2024 | Other filings | ASX |
|---|
| Positive topline results from ph2b in head & neck cancer | Jun 26, 2024 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Jun 25, 2024 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jun 24, 2024 | Current report | SEC |
|---|
| Immutep completes underwritten retail entitlement offer | Jun 24, 2024 | Financing | ASX |
|---|
| 6-K · Report of a foreign issuer | Jun 5, 2024 | Current report | SEC |
|---|
| Immutep completes institutional pro-rata offer & placement | Jun 4, 2024 | Financing | ASX |
|---|
| 6-K · Report of a foreign issuer | Jun 4, 2024 | Current report | SEC |
|---|
| Immutep announces Ph 3 clinical trial collaboration with MSD | Jun 3, 2024 | Operations update | ASX |
|---|
| Immutep Capital Raising Presentation | Jun 2, 2024 | Financing | ASX |
|---|
| A$100 million fully underwritten equity raising | Jun 2, 2024 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | May 15, 2024 | Current report | SEC |
|---|
| AIPAC-003 safety lead-in data presented at ESMO Breast 2024 | May 15, 2024 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | May 2, 2024 | Current report | SEC |
|---|
| Positive initial data in phase 2 Soft Tissue Sarcoma trial | May 1, 2024 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Apr 30, 2024 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Apr 24, 2024 | Current report | SEC |
|---|
| Positive preliminary topline results from TACTI-003 Cohort B | Apr 23, 2024 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Apr 18, 2024 | Current report | SEC |
|---|
| CHDR to conduct first-in-human phase 1 trial of IMP761 | Apr 17, 2024 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Mar 5, 2024 | Current report | SEC |
|---|
| First Clinical Data announced from 90mg Dosing of Efti | Mar 5, 2024 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Feb 29, 2024 | Current report | SEC |
|---|
| SC 13G/A · Big-stake notice, amended | Feb 9, 2024 | Big-stake notice | SEC |
|---|
| 6-K · Report of a foreign issuer | Jan 30, 2024 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Dec 21, 2023 | Current report | SEC |
|---|
| PEI provides constructive feedback for ph3 lung cancer trial | Dec 20, 2023 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Dec 7, 2023 | Current report | SEC |
|---|
| Immutep receives A$2.6 million French R&D Tax Incentive | Dec 6, 2023 | Financing | ASX |
|---|
| 6-K · Report of a foreign issuer | Nov 9, 2023 | Current report | SEC |
|---|
| Immutep Completes Enrolment for TACTI-003 Phase IIb Trial | Nov 8, 2023 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Nov 6, 2023 | Current report | SEC |
|---|
| Lead-in phase completed for ph2/3 trial in Breast Cancer | Nov 5, 2023 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Nov 3, 2023 | Current report | SEC |
|---|
| New Biomarker Data from TACTI-002 trial in 1st line NSCLC | Nov 2, 2023 | Operations update | ASX |
|---|
| 6-K · Report of a foreign issuer | Oct 31, 2023 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Oct 25, 2023 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Oct 24, 2023 | Current report | SEC |
|---|
| 20-F · Annual report | Oct 24, 2023 | Annual report | SEC |
|---|
| 6-K · Report of a foreign issuer | Oct 24, 2023 | Current report | SEC |
|---|
| Immutep reports promising data from INSIGHT-003 trial | Oct 23, 2023 | Operations update | ASX |
|---|
| Webcast slides for new Efti clinical data in 1st line NSCLC | Oct 22, 2023 | Operations update | ASX |
|---|
| Excellent Overall Survival in Non-Small Cell Lung Cancer | Oct 22, 2023 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Oct 16, 2023 | Current report | SEC |
|---|
| Immutep announces publication of ESMO 2023 abstracts | Oct 15, 2023 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Sep 21, 2023 | Current report | SEC |
|---|
| Commercial Scale Manufacturing of Efti for Clinical Trials | Sep 20, 2023 | Other filings | ASX |
|---|
| Appendix 4E & 2023 Full Year Statutory Accounts | Aug 29, 2023 | Annual report | ASX |
|---|
| 6-K · Report of a foreign issuer | Aug 1, 2023 | Current report | SEC |
|---|
| Immutep receives positive scientific advice from EMA | Aug 1, 2023 | Other filings | ASX |
|---|
| 6-K · Report of a foreign issuer | Jul 31, 2023 | Current report | SEC |
|---|
| 6-K · Report of a foreign issuer | Jul 28, 2023 | Current report | SEC |
|---|
| 1st Patient Dosed in Phase 2 Soft Tissue Sarcoma Trial | Jul 27, 2023 | Other filings | ASX |
|---|
This page holds 200 of 1,037 filings.
All of its filings on SEC EDGAR